Below Are the CLSI Breakpoints for Selected Bacteria. Please Use Your Clinical Judgement When Assessing Breakpoints

Total Page:16

File Type:pdf, Size:1020Kb

Below Are the CLSI Breakpoints for Selected Bacteria. Please Use Your Clinical Judgement When Assessing Breakpoints Below are the CLSI breakpoints for selected bacteria. Please use your clinical judgement when assessing breakpoints. The lowest number does NOT equal most potent antimicrobial. Contact Antimicrobial Stewardship for drug selection and dosing questions. Table 1: 2014 MIC Interpretive Standards for Enterobacteriaceae (includes E.coli, Klebsiella, Enterobacter, Citrobacter, Serratia and Proteus spp) Antimicrobial Agent MIC Interpretive Criteria (g/mL) Enterobacteriaceae S I R Ampicillin ≤ 8 16 ≥ 32 Ampicillin-sulbactam ≤ 8/4 16/8 ≥ 32/16 Aztreonam ≤ 4 8 ≥ 16 Cefazolin (blood) ≤ 2 4 ≥ 8 Cefazolin** (uncomplicated UTI only) ≤ 16 ≥ 32 Cefepime* ≤ 2 4-8* ≥ 16 Cefotetan ≤ 16 32 ≥ 64 Ceftaroline ≤ 0.5 1 ≥ 2 Ceftazidime ≤ 4 8 ≥ 16 Ceftriaxone ≤ 1 2 ≥ 4 Cefpodoxime ≤ 2 4 ≥ 8 Ciprofloxacin ≤ 1 2 ≥ 4 Ertapenem ≤ 0.5 1 ≥ 2 Fosfomycin ≤ 64 128 ≥256 Gentamicin ≤ 4 8 ≥ 16 Imipenem ≤ 1 2 ≥ 4 Levofloxacin ≤ 2 4 ≥ 8 Meropenem ≤ 1 2 ≥ 4 Piperacillin-tazobactam ≤ 16/4 32/4 – 64/4 ≥ 128/4 Trimethoprim-sulfamethoxazole ≤ 2/38 --- ≥ 4/76 *Susceptibile dose-dependent – see chart below **Cefazolin can predict results for cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil, cephalexin and loracarbef for uncomplicated UTIs due to E.coli, K.pneumoniae, and P.mirabilis. Cefpodoxime, cefinidir, and cefuroxime axetil may be tested individually because some isolated may be susceptible to these agents while testing resistant to cefazolin. Cefepime dosing for Enterobacteriaceae ( E.coli, Klebsiella, Enterobacter, Citrobacter, Serratia & Proteus spp) Susceptible Susceptible –dose-dependent (SDD) Resistant MIC </= 2 4 8 >/= 16 Based on dose of: 1g q12h 1g every 8h or 2g every 8 h Do not give 2g q12 Total dose 2g 3-4g 6g NA Table 2: 2014 MIC Interpretive Standards for Pseudomonas aeruginosa and Acinetobacter spp. Antimicrobial Agent MIC Interpretive Criteria (g/mL) Pseudomonas aeruginosa S I R Amikacin ≤ 16 32 ≥ 64 Aztreonam ≤ 8 16 ≥ 32 Cefepime ≤ 8 16 ≥ 32 Ceftazdime ≤ 8 16 ≥ 32 Ciprofloxacin ≤ 1 2 ≥ 4 Colistin/Polymixin B(Pseudomonas) ≤ 2 4 ≥ 8 Colistin/ Polymixin B (Acinetobacter) ≤ 2 ≥ 4 Gentamicin ≤ 4 8 ≥ 16 Imipenem ≤ 2 4 ≥ 8 Levofloxacin ≤ 2 4 ≥ 8 Meropenem ≤ 2 4 ≥ 8 Minocycline (Acinetobacter only) ≤ 4 8 ≥ 16 Piperacillin-tazobactam ≤ 16/4 32/4 – 64/4 ≥ 128/4 Ticarcillin-clavulanic acid ≤ 16/2 32/2 – 64/2 ≥ 128/2 Tobramycin ≤ 4 8 ≥ 16 GRAM POSITIVES Table 3: 2014 MIC Interpretive Standards for S.aureus. Antimicrobial Agent MIC Interpretive Criteria (g/mL) S.aureus S I R Ceftaroline ≤ 1 2 ≥ 4 Clindamycin ≤ 0.5 1-2 ≥ 4 Erythromycin ≤ 0.5 1-4 ≥ 8 Gentamicin ≤ 4 8 ≥ 16 Levofloxacin ≤ 1 2 ≥ 4 Moxifloxacin ≤ 0.5 1 ≥ 2 Oxacillin* ≤ 2 ≥ 4 Penicillin ≤ 0.12 ≥ 0.25 Rifampin ≤ 1 2 ≥ 4 Tetracycline ≤ 4 8 ≥ 16 Trimethoprim/Sulfamethoxazole ≤ 2/38 ≥ 4/76 Vancomycin ≤ 2 4-8 ≥ 16 Daptomycin ≤ 1 Linezolid ≤ 4 ≥ 8 *Rifampin should not be used for monotherapy ** If oxacillin susceptible, then results can applied to other beta-lactams including cephalosporins. Table 4: 2014 MIC Interpretive Standards for Enterococcus species. Antimicrobial Agent MIC Interpretive Criteria (g/mL) Enterococcus spp S I R Ampicillin*** ≤ 8 ≥ 16 Daptomycin ≤ 4 Doxycycline ≤ 4 8 ≥ 16 Erythromycin ≤ 0.5 1-4 ≥ 8 Gentamicin Synergy or no synergy Linezolid ≤ 2 4 ≥ 8 Penicillin** ≤ 8 ≥ 16 Quinapristin-dalfopristin ≤ 1 2 ≥ 4 (Synercid) Rifampin ≤ 1 2 ≥ 4 Streptomycin Synergy or no synergy Vancomycin ≤ 4 8-16 ≥ 32 *For enterococcus, cephalosporins, aminoglycosides (except for high-level resistance screening), clindamycin, and trimethoprim- sulfamethoxazole are not effective clinically. **Call microbiology lab for penicillin MIC. ***Ampicillin susceptibility testing predicts activity of amoxicillin, amoxicillin-clavulanate, ampicillin-sulbactam, piperacillin, and piperacillin-tazobactam. Ampicillin susceptibility can be used to predict imipenem susceptibility provided the species is E.faecalis. .
Recommended publications
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • “Ceftriaxone– Sulbactam–EDTA” and Various Antibiotics Against Gram
    ORIGINAL ARTICLE A Comparative In Vitro Sensitivity Study of “Ceftriaxone– Sulbactam–EDTA” and Various Antibiotics against Gram- negative Bacterial Isolates from Intensive Care Unit Sweta Singh1, Chinmoy Sahu2, Sangram Singh Patel3, Abhay Singh4, Nidhi Yaduvanshi5 ABSTRACT Introduction: A rapid increase in multidrug-resistant (MDR) strains is being seen across the globe especially in the Southeast Asian region, including India. Carbapenems and colistin form the mainstay of treatment against gram-negative pathogens, especially extended-spectrum beta-lactamase (ESBL)- and metallo-beta-lactamse (MBL)-producing isolates. However, due to increased resistance to carbapenems and toxicity of colistin, especially in intensive care units (ICUs), carbapenem-sparing antibiotics like ceftriaxone–sulbactam–EDTA (CSE) combination needs to be evaluated. Materials and methods: Bacterial isolates cultured from various clinical samples from all ICUs for a period of 9 months were evaluated. Bacterial identification was performed by matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) and antibiotic susceptibility testing were performed by disk diffusion and E test method. Antibiogram of various antibiotics was noted. Extended-spectrum beta-lactamase- and MBL-producing bacteria were identified by phenotypic methods. Antibiotic sensitivity results of CSE were compared with the comparator drugs like colistin, carbapenems, and tigecycline in Enterobacteriaceae, Acinetobacter spp., and Pseudomonas spp. along with ESBL and MBL producers. Results: A total of 2,760 samples of blood, cerebrospinal fluid (CSF), respiratory samples, tissue, and pus were collected from ICUs with maximum isolates from pus (37%) followed by respiratory samples (31%) and blood (27%). Escherichia coli and Klebsiella pneumoniae were the predominant gram-negative pathogens accounting for 56% of the isolates followed by Acinetobacter spp.
    [Show full text]
  • Cefoxitin Versus Piperacillin– Tazobactam As Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy: Protocol for a Randomised Controlled Trial
    Open access Protocol BMJ Open: first published as 10.1136/bmjopen-2020-048398 on 4 March 2021. Downloaded from Cefoxitin versus piperacillin– tazobactam as surgical antibiotic prophylaxis in patients undergoing pancreatoduodenectomy: protocol for a randomised controlled trial Nicole M Nevarez ,1 Brian C Brajcich,2 Jason Liu,2,3 Ryan Ellis,2 Clifford Y Ko,2 Henry A Pitt,4 Michael I D'Angelica,5 Adam C Yopp1 To cite: Nevarez NM, ABSTRACT Strengths and limitations of this study Brajcich BC, Liu J, et al. Introduction Although antibiotic prophylaxis is Cefoxitin versus piperacillin– established in reducing postoperative surgical site tazobactam as surgical ► A major strength of this study is the multi- infections (SSIs), the optimal antibiotic for prophylaxis in antibiotic prophylaxis institutional, double- arm, randomised controlled in patients undergoing pancreatoduodenectomy (PD) remains unclear. The study trial design. objective is to evaluate if administration of piperacillin– pancreatoduodenectomy: ► A limitation of this study is that all perioperative care protocol for a randomised tazobactam as antibiotic prophylaxis results in decreased is at the discretion of the operating surgeon and is controlled trial. BMJ Open 30- day SSI rate compared with cefoxitin in patients not standardised. 2021;11:e048398. doi:10.1136/ undergoing elective PD. ► All data will be collected through the American bmjopen-2020-048398 Methods and analysis This study will be a multi- College of Surgeons National Surgical Quality ► Prepublication history for institution, double- arm, non- blinded randomised controlled Improvement Program, which is a strength for its this paper is available online. superiority trial. Adults ≥18 years consented to undergo PD ease of use but a limitation due to the variety of data To view these files, please visit for all indications who present to institutions participating included.
    [Show full text]
  • Antimicrobial Susceptibility Among Colistin, Sulbactam, And
    Hindawi Journal of Pathogens Volume 2018, Article ID 3893492, 5 pages https://doi.org/10.1155/2018/3893492 Research Article Antimicrobial Susceptibility among Colistin, Sulbactam, and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii Sombat Leelasupasri,1 Wichai Santimaleeworagun ,2,3 and Tossawan Jitwasinkul3,4 1 Internal Medicine Unit, Phyathai II International Hospital, Bangkok, Tailand 2Department of Pharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Tailand 3Antibiotic Optimization and Patient Care Project by Pharmaceutical Initiative for Resistant Bacteria and Infectious Diseases Working Group (PIRBIG), Silpakorn University, Nakhon Pathom, Tailand 4Department of Biopharmacy, Faculty of Pharmacy, Silpakorn University, Nakhon Pathom, Tailand Correspondence should be addressed to Wichai Santimaleeworagun; [email protected] Received 28 August 2017; Revised 9 December 2017; Accepted 25 December 2017; Published 18 January 2018 Academic Editor: Jose Yuste Copyright © 2018 Sombat Leelasupasri et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Tis in vitro study aimed to determine the activity of colistin plus sulbactam and colistin plus fosfomycin against carbapenem- resistant A. baumannii (CRAB). Fifeen clinical isolates were obtained from patients admitted to Phyathai II International Hospital, Bangkok, Tailand, from August 2014 to April 2015. Te antimicrobial susceptibilities of colistin, sulbactam, and fosfomycin were evaluated using the E-test or broth microdilution and the synergistic activity of the antibacterial combinations (colistin plus sulbactam or fosfomycin) was determined using the chequerboard method. Clonal relationships were explored using repetitive element palindromic- (REP-) PCR.
    [Show full text]
  • Cefalexin in the WHO Essential Medicines List for Children Reject
    Reviewer No. 1: checklist for application of: Cefalexin In the WHO Essential Medicines List for Children (1) Have all important studies that you are aware of been included? Yes No 9 (2) Is there adequate evidence of efficacy for the proposed use? Yes 9 No (3) Is there evidence of efficacy in diverse settings and/or populations? Yes 9 No (4) Are there adverse effects of concern? Yes 9 No (5) Are there special requirements or training needed for safe/effective use? Yes No 9 (6) Is this product needed to meet the majority health needs of the population? Yes No 9 (7) Is the proposed dosage form registered by a stringent regulatory authority? Yes 9 No (8) What action do you propose for the Committee to take? Reject the application for inclusion of the following presentations of cefalexin: • Tablets/ capsules 250mg • Oral suspensions 125mg/5ml and 125mg/ml (9) Additional comment, if any. In order to identify any additional literature, the following broad and sensitive search was conducted using the PubMed Clinical Query application: (cephalexin OR cefalexin AND - 1 - pediatr*) AND ((clinical[Title/Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) Only one small additional study was identified, which looked at the provision of prophylactic antibiotics in patients presenting to an urban children's hospital with trauma to the distal fingertip, requiring repair.1 In a prospective randomised control trial, 146 patients were enrolled, of which 69 were randomised to the no-antibiotic group, and 66 were randomised to the antibiotic (cefalexin) group.
    [Show full text]
  • Ladenburg Thalmann Healthcare Conference
    Ladenburg Thalmann Healthcare Conference July 13, 2021 Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the design, initiation, timing and submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; expected broad access across payer channels for tebipenem HBr; the expected pricing of tebipenem HBr and the anticipated shift in treating patients from intravenous to oral administration; the initiation, timing, progress and results of the Company’s preclinical studies and clinical trials and its research and development programs, including management’s assessment of such results; the direct and indirect impact of the pandemic caused by an outbreak of a new strain of coronavirus on the Company’s business and operations; the timing of the availability of data from the Company’s clinical trials; the timing of the Company’s filings with regulatory agencies; product candidate benefits; competitive position; business strategies; objectives of management; potential growth opportunities; potential market size; reimbursement matters; possible or assumed future results of operations; projected costs; and the Company’s cash forecast and the availability of additional non-dilutive funding from governmental agencies beyond any initially funded awards. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions.
    [Show full text]
  • Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the Β-Lactamase Inhibitor LN-1-255 Against Acinetobacter Spp
    antibiotics Article Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the β-Lactamase Inhibitor LN-1-255 against Acinetobacter spp. Cristina Lasarte-Monterrubio 1,† , Juan C. Vázquez-Ucha 1,† , Maria Maneiro 2, Jorge Arca-Suárez 1,*, Isaac Alonso 3, Paula Guijarro-Sánchez 1 , John D. Buynak 4, Germán Bou 1, Concepción González-Bello 2 and Alejandro Beceiro 1,* 1 Servicio de Microbiología, Instituto de Investigación Biomédica de A Coruña (INIBIC-CICA), Complejo Hospitalario Universitario A Coruña (CHUAC), As Xubias 84, 15006 A Coruña, Spain; [email protected] (C.L.-M.); [email protected] (J.C.V.-U.); [email protected] (P.G.-S.); [email protected] (G.B.) 2 Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, Jenaro de la Fuente s/n, 15782 Santiago de Compostela, Spain; [email protected] (M.M.); [email protected] (C.G.-B.) 3 Servicio de Microbiología, Hospital Provincial Pontevedra, Loureiro Crespo 2, 36002 Pontevedra, Spain; Citation: Lasarte-Monterrubio, C.; [email protected] 4 Vázquez-Ucha, J.C.; Maneiro, M.; Department of Chemistry, Southern Methodist University, Dallas, TX 75275, USA; [email protected] Arca-Suárez, J.; Alonso, I.; * Correspondence: [email protected] (J.A.-S.); [email protected] (A.B.); Tel.: +34-981-176-087 (J.A.-S.); +34-981-176-087 (A.B.) Guijarro-Sánchez, P.; Buynak, J.D.; † Cristina Lasarte-Monterrubio and Juan C. Vázquez-Ucha contributed equally to the study. Bou, G.; González-Bello, C.; Beceiro, A.
    [Show full text]
  • Severe Sepsis and Septic Shock Antibiotic Guide
    Stanford Health Issue Date: 05/2017 Stanford Antimicrobial Safety and Sustainability Program Severe Sepsis and Septic Shock Antibiotic Guide Table 1: Antibiotic selection options for healthcare associated and/or immunocompromised patients • Healthcare associated: intravenous therapy, wound care, or intravenous chemotherapy within the prior 30 days, residence in a nursing home or other long-term care facility, hospitalization in an acute care hospital for two or more days within the prior 90 days, attendance at a hospital or hemodialysis clinic within the prior 30 days • Immunocompromised: Receiving chemotherapy, known systemic cancer not in remission, ANC <500, severe cell-mediated immune deficiency Table 2: Antibiotic selection options for community acquired, immunocompetent patients Table 3: Antibiotic selection options for patients with simple sepsis, community acquired, immunocompetent patients requiring hospitalization. Risk Factors for Select Organisms P. aeruginosa MRSA Invasive Candidiasis VRE (and other resistant GNR) Community acquired: • Known colonization with MDROs • Central venous catheter • Liver transplant • Prior IV antibiotics within 90 day • Recent MRSA infection • Broad-spectrum antibiotics • Known colonization • Known colonization with MDROs • Known MRSA colonization • + 1 of the following risk factors: • Prolonged broad antibacterial • Skin & Skin Structure and/or IV access site: ♦ Parenteral nutrition therapy Hospital acquired: ♦ Purulence ♦ Dialysis • Prolonged profound • Prior IV antibiotics within 90 days ♦ Abscess
    [Show full text]
  • The Antibacterial Activity of Cefpodoxime and the Novel Β
    Session-198 b SATURDAY-279 The Antibacterial Activity of Cefpodoxime and the Novel -lactamase Inhibitor ETX1317 Against Recent Clinical Isolates of b-lactamase-producing Enterobacteriaceae Entasis Therapeutics S. McLeod1, M. Hackel2, R. Badal2, A. Shapiro1, J. Mueller1, R. Tommasi1, and A. Miller1 1-781-810-0120 1Entasis Therapeutics, Waltham, MA and 2IHMA, International Health Management Associates, Schaumburg, IL USA www.entasistx.com Abstract In vitro activity of ETX1317 vs. comparator BLIs Cumulative activity vs. 911 ESBL-enriched Enterobacteriaceae from 2013-2015 Activity vs. 35 sequenced KPC+ and/or MBL+ Enterobacteriaceae MIC (mg/L) Background β-lactamase inhibition (IC50, µM) Strain ID Species encoded bla genes IPM CAZ-AVI CPD-ETX1317 ETX1317 ETX1317 is a novel, diazabicyclooctenone inhibitor of serine β-lactamases that Number (cumulative %) of isolates inhibited at MIC (mg/L) Class A Class C Class D Drug %S* ARC3528*¥ E. cloacae AmpC [∆308-313(SKVALA)] 0.25 32 0.125 4 restores β-lactam activity against multidrug-resistant Enterobacteriaceae. ETX0282, < 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 > 32 ARC4165*¥ C. freundii CMY-2; AmpC [N366Y]; TEM-1; SHV-5 2 32 ≤0.03 4 the oral prodrug of ETX1317, is currently under investigation in combination with BLI CTX-M-15 SHV-5 KPC-2 TEM-1 AmpC* P99 OXA-24/40 OXA-48 0 5 6 14 19 34 20 27 17 18 18 733 3 CPD 10.8 ARC6479* K. oxytoca NDM-1 16 >32 32 32 cefpodoxime proxetil (CPDP), which is hydrolyzed in vivo to release cefpodoxime 0% 0.5% 1% 3% 5% 9% 11% 14% 16% 18% 20% 100% (CPD).
    [Show full text]
  • Severe Sepsis Tipsheet
    Severe Sepsis Tipsheet SEVERE SEPSIS A, B, and C of the following must be met within 6 hours of each other. A. Documentation of a suspected infection. There may be reference to “possible infection,” “suspect infection,” “rule out infection,” or similar documentation. B. TWO or more manifestations of systemic infection according to the Systemic Inflammatory Response Syndrome (SIRS) criteria, which are: • Temperature > 38.3 C or < 36.0 C (> 100.9 F or < 96.8 F) • Heart rate (pulse) > 90 • Respiration > 20 per minute • White blood cell count > 12,000 or < 4,000 or > 10% bands C. Organ dysfunction, evidenced by any one of the following: • Systolic blood pressure (SBP) < 90 mmHg, or mean arterial pressure < 65 mmHg, or a systolic blood pressure decrease of more than 40 mmHg. Physician/APN/PA documentation must be present in the medical record indicating a > 40 mmHg decrease in SBP has occurred and is related to infection, severe sepsis or septic shock and not other causes. • Acute respiratory failure as evidenced by a new need for invasive or non-invasive mechanical ventilation. To use acute respiratory failure as a sign of organ dysfunction there must be: • Documentation of acute respiratory failure AND • Documentation the patient is on mechanical ventilation • Invasive mechanical ventilation requires an endotracheal or tracheostomy tube. Non-invasive mechanical ventilation may be referred to as BiPAP or CPAP. • New need for mechanical ventilation indicates the patient was not using the same type of mechanical ventilation prior to the current acute respiratory failure. • Use the time at which there is documentation the patient has both acute respiratory failure and is on mechanical ventilation.
    [Show full text]
  • Antimicrobial Stewardship Guidance
    Antimicrobial Stewardship Guidance Federal Bureau of Prisons Clinical Practice Guidelines March 2013 Clinical guidelines are made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant these guidelines for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Consult the BOP Clinical Practice Guidelines Web page to determine the date of the most recent update to this document: http://www.bop.gov/news/medresources.jsp Federal Bureau of Prisons Antimicrobial Stewardship Guidance Clinical Practice Guidelines March 2013 Table of Contents 1. Purpose ............................................................................................................................................. 3 2. Introduction ...................................................................................................................................... 3 3. Antimicrobial Stewardship in the BOP............................................................................................ 4 4. General Guidance for Diagnosis and Identifying Infection ............................................................. 5 Diagnosis of Specific Infections ........................................................................................................ 6 Upper Respiratory Infections (not otherwise specified) ..............................................................................
    [Show full text]
  • Penicillin Allergy Guidance Document
    Penicillin Allergy Guidance Document Key Points Background Careful evaluation of antibiotic allergy and prior tolerance history is essential to providing optimal treatment The true incidence of penicillin hypersensitivity amongst patients in the United States is less than 1% Alterations in antibiotic prescribing due to reported penicillin allergy has been shown to result in higher costs, increased risk of antibiotic resistance, and worse patient outcomes Cross-reactivity between truly penicillin allergic patients and later generation cephalosporins and/or carbapenems is rare Evaluation of Penicillin Allergy Obtain a detailed history of allergic reaction Classify the type and severity of the reaction paying particular attention to any IgE-mediated reactions (e.g., anaphylaxis, hives, angioedema, etc.) (Table 1) Evaluate prior tolerance of beta-lactam antibiotics utilizing patient interview or the electronic medical record Recommendations for Challenging Penicillin Allergic Patients See Figure 1 Follow-Up Document tolerance or intolerance in the patient’s allergy history Consider referring to allergy clinic for skin testing Created July 2017 by Macey Wolfe, PharmD; John Schoen, PharmD, BCPS; Scott Bergman, PharmD, BCPS; Sara May, MD; and Trevor Van Schooneveld, MD, FACP Disclaimer: This resource is intended for non-commercial educational and quality improvement purposes. Outside entities may utilize for these purposes, but must acknowledge the source. The guidance is intended to assist practitioners in managing a clinical situation but is not mandatory. The interprofessional group of authors have made considerable efforts to ensure the information upon which they are based is accurate and up to date. Any treatments have some inherent risk. Recommendations are meant to improve quality of patient care yet should not replace clinical judgment.
    [Show full text]